Objectives
To achieve the envisaged advances in the management and treatment of ulcerative colitis and atopic dermatitis, the following objectives have been defined:
- To strengthen the knowledge base and support advancements in the field of immune-mediated inflammatory diseases
- To improve the competitiveness of European industry and support the development and evaluation of biomarkers that could be used in large clinical trials longitudinally
- To conduct a comprehensive molecular characterisation of intestinal/dermal microenvironment and immune cell profiles providing a data foundation for advanced bioinformatics as well as statistical and model-based analyses
- To confirm the identified signatures in tissue and blood samples from a large retrospective and longitudinal cohort and in a non-interventional prospective clinical study
- To evaluate evolving technologies such as dermal open-flow microperfusion and ultrasound-enabled gut liquid biopsy as non-invasive approaches for the identification of new microenvironmental biomarkers suitable to reflect clinically relevant tissue-based signatures of disease progression and/or response to treatment
- To establish an integrated large-scale platform for data storage and computing to collect, curate, harmonise and standardise existing and newly generated data in a secure data and analysis platform on secured servers